Top-Funded Cardiac AI Startups: Investor’s Guide to Heart Health Innovation

A ton of VC money in healthcare AI is getting piled into just a few companies, especially the ones claiming they can fix chronic disease management. If you’re investing, you have to track where the smart money in heart disease prevention is going so you can find the platforms that will actually last. We’ve been tracking the top AI startups in this space and put together a ranking based on total capital raised and current valuation.

The Leaders in Cardiac AI Funding

In digital health, who backs you is everything. Getting a check from a top healthcare AI venture firm tells the market you’re for real. Our own tracker shows a huge gap opening up between the leaders and everyone else in AI for cardiovascular prevention.

Right now, two companies are miles ahead in funding and valuation:

• Tempus AI: With an insane $11.18 billion valuation and GV’s backing, Tempus is the prime example of how AI can be used in precision medicine. They’re expanding into areas that can directly inform heart disease prevention by digging into genomic and phenotypic data. SEC filings for Tempus AI
• Viz.ai: Now valued at $1.2 billion after its Series D, Viz.ai has locked down the market for AI-driven clinical workflows. With Tiger Global’s support, they’re dominant in stroke and pulmonary embolism, which has a ripple effect on cardiovascular health by making acute care faster and stopping secondary cardiac events before they happen. Viz.ai Series D funding press release

Neither of these companies started out to be a “primary heart disease prevention” platform, but that’s not the point. The insights they pull from data and the efficiencies they create in hospital workflows are the building blocks you need for any real, personalized patient care strategy that actually prevents disease.

Comparative Funding Tracker: Tempus AI vs. Viz.ai

Looking at how these two leaders got funded gives investors a map of the healthcare AI venture space. It shows what the market values right now and who has the big VCs behind them:

AI Health Investments Tracker: Top-Funded AI in Cardiovascular-Adjacent Prevention

• Tempus AI
  • Valuation: $11.18 Billion
  • Key Investor: GV
  • Focus Area: Precision medicine using genomic and clinical data to personalize care, with direct relevance for risk-stratifying patients for chronic illnesses like heart disease.
  • Impact on Prevention: Tempus’s platform can spot genetic risks and find the best treatment paths from individual patient data, allowing doctors to create highly specific preventive plans.
• Viz.ai
  • Valuation: $1.2 Billion
  • Key Investor: Tiger Global
  • Focus Area: AI-powered software for coordinating care and speeding up workflows for acute problems like stroke and pulmonary embolism.
  • Impact on Prevention: Viz.ai is built for emergencies, but by getting patients diagnosed and treated faster for a critical cardiovascular event, it cuts down on long-term damage and death, which prevents a cascade of future cardiac problems and improves a patient’s overall heart health.

These valuations aren’t just big numbers. They show the market believes these companies can build solutions that reach across the health system. Tempus AI’s huge valuation is a bet on the demand for deep data insights, starting in oncology but with obvious potential to cross over into any complex chronic disease where your genes and clinical history can predict trouble early. Viz.ai’s billion-dollar success, on the other hand, shows how much investors will pay for an AI that just makes a critical, chaotic hospital workflow simpler, saving lives and making the hospital run better.

The Cautionary Tale: Olive AI

Not all the high-flyers stick the landing. Some crash and burn. Look at Olive AI, it’s a brutal reminder that raising a ton of money doesn’t mean you’ve won. Olive AI pulled in around $902 million and then went into a complete shutdown. Olive AI liquidation reports

Olive was focused on back-office automation, a different problem than clinical heart disease prevention, but the lessons for investors are the same:

• Capital Efficiency: A huge funding round is useless if you just burn through it. The company has to be able to use that cash to actually grow and get a foothold in the market. Raising nearly a billion dollars like Olive AI and still going to zero proves this point.
• Clinical Outcomes and Payer Contracts: Our internal analysis shows this again and again: companies that survive have published clinical outcomes and real payer contracts. Olive had a hard time showing a clear, dollars-and-cents ROI to hospital CFOs.
• Problem-Solution Fit: You need to solve a specific, painful problem with a measurable result. The market is screaming for this. While hospital paperwork is a huge burden, Olive’s solution was apparently too complex or didn’t deliver enough obvious value to get traction.

The lesson here is simple. Investors have to get past the headline funding number and start asking hard questions about the business model, the regulatory plan (do they have a 510(k)? A De Novo pathway?), and the proof that it actually works in a real hospital.

Beyond Funding: Evaluating Capital Efficiency and Clinical Adoption

So for VCs and other investors, the takeaway is to stop looking at just the total funding when you’re sizing up an AI startup in the heart disease space. A big valuation is nice, but long-term survival depends on a few other things that are much harder to fake:

• Clinical Validation: Show me the data. I want to see tangible, published clinical outcomes that de-risk the investment. This means real studies and peer-reviewed papers, along with Real-World Evidence (RWE) proving the AI actually works and is safe.
• Payer Contracts and Reimbursement Pathways: How do you get paid? An AI solution is dead on arrival without a clear path to reimbursement. You need to have a strategy for securing CPT Codes (Category I or III) and working through the reimbursement maze (like NTAP for inpatient tech).
• Regulatory Clarity: The team has to know the regulatory game. You need to see a clear plan for the FDA pathway (is it SaMD? are they using GMLP?) and proof they can manage a QMS or get ISO 13485 certified. A Breakthrough Device Designation or a 510(k) clearance shows they’re serious and lowers investor risk significantly. A plan for managing the AI model over time, like a PCCP, is a huge plus.
• Data Moat and Algorithmic Durability: Having your own proprietary dataset is a massive competitive advantage because it makes it almost impossible for someone else to copy your algorithm’s performance. The company also needs a serious plan to watch for Algorithmic Drift to make sure their models don’t get worse over time.
• Capital Efficiency: I’d rather see a company hit its milestones on a smaller amount of capital than a company that burns through hundreds of millions just to stay afloat. It’s a much better sign of long-term health. A smart “wedge product” strategy, where they dominate a small, specific use case first, is a great indicator of capital efficiency.

The AI health companies you really want to invest in have big funding, sure, but they also have a realistic plan for getting used in hospitals, proof that they help patients, and a business model that gets them paid by insurers.

Methodology

We put this analysis together using our own venture capital databases, public financial disclosures, and regulatory filings we could verify. Our rankings combine data on funding rounds, who the key investors are, and reported valuations to give you a clear picture of where the money is going in healthcare AI, especially for anything related to cardiovascular health.